By regulating miR-182-5p/&lt;i&gt;BCL10&lt;/i&gt;/&lt;i&gt;CYCS&lt;/i&gt;, sufentanil reduces the apoptosis of umbilical cord mesenchymal stem cells caused by ropivacaine

Li, Lisha; Sun, Yan; Zhang, Na; Wang, Ling; Luo, Qingyan

doi:10.5582/bst.2018.01291

Cited by 13 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interactions have been observed in other drugs commonly used in clinical practice. Li et al documented that ropivacaine inhibits cellular viability and induces apoptosis, whereas concomitant use of sufentanil mitigates its action by means of miRNA-182-5p/BCL10/CYCS regulation [ 176 ]. Qu et al suggest that the beneficial effects of lidocaine on colorectal cancer could be mediated by the upregulation of miRNA-520 a-3p and targeting EGFR [ 177 ].…”

Section: Biomarkers Anaesthetic Technique and Cancermentioning

confidence: 99%

Breast Cancer and Anaesthesia: Genetic Influence

Ponferrada

Orriach

Ruiz

et al. 2021

IJMS

View full text Add to dashboard Cite

Breast cancer is the leading cause of mortality in women. It is a heterogeneous disease with a high degree of inter-subject variability even in patients with the same type of tumor, with individualized medicine having acquired significant relevance in this field. The clinical and morphological heterogeneity of the different types of breast tumors has led to a diversity of staging and classification systems. Thus, these tumors show wide variability in genetic expression and prognostic biomarkers. Surgical treatment is essential in the management of these patients. However, the perioperative period has been found to significantly influence survival and cancer recurrence. There is growing interest in the pro-tumoral effect of different anaesthetic and analgesic agents used intraoperatively and their relationship with metastatic progression. There is cumulative evidence of the influence of anaesthetic techniques on the physiopathological mechanisms of survival and growth of the residual neoplastic cells released during surgery. Prospective randomized clinical trials are needed to obtain quality evidence on the relationship between cancer and anaesthesia. This document summarizes the evidence currently available about the effects of the anaesthetic agents and techniques used in primary cancer surgery and long-term oncologic outcomes, and the biomolecular mechanisms involved in their interaction.

show abstract

Section: Biomarkers Anaesthetic Technique and Cancermentioning

confidence: 99%

Breast Cancer and Anaesthesia: Genetic Influence

Ponferrada

Orriach

Ruiz

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…As LD and BP inhibit ion channels, the observed alternation in the gene expressions may be associated with ion transport. Likewise, several previous studies suggest that ion channels play roles in cell cycle, metabolism, and mechanotransduction of MSCs, PDLSCs, and TSCs [ 3 , 32 – 34 ]. Yet, we cannot rule out the possibility that LD and BP may interact with certain receptors in the stem/progenitor cells directly or indirectly.…”

Section: Discussionmentioning

confidence: 94%

Effect of local anesthetics on viability and differentiation of various adult stem/progenitor cells

et al. 2020

View full text Add to dashboard Cite

Background Local anesthetics (LAs) are widely used to control pain during various clinical treatments. One of the side effects of LAs, cytotoxicity, has been investigated in various cells including stem/progenitor cells. However, our understanding of the effects of LAs on the differentiation capacity of stem/progenitor cells still remains limited. Therefore, a comparative study was conducted to investigate the effects of multiple LAs on viability and multi-lineage differentiation of stem/progenitor cells that originated from various adult tissues. Method Multiple types of stem/progenitor cells, including bone marrow mesenchymal stem/progenitor cells (MSCs), dental pulp stem/progenitor cells (DPSCs), periodontal ligament stem/progenitor cells (PDLSCs), and tendon-derived stem/progenitor cells, were either obtained from a commercial provider or isolated from adult human donors. Lidocaine (LD) and bupivacaine (BP) at various doses (1×, 0.75×, 0.5×, and 0.25× of each physiological dose) were applied to the different stem/progenitor cells for an hour, followed by induction of fibrogenic, chondrogenic, osteogenic, and adipogenic differentiation. Live/dead and MTT assays were performed at 24 h after the LD or BP treatment. At 2 weeks, qRT-PCR was conducted to evaluate the gene expressions associated with differentiation. After 4 weeks, multiple biochemical staining was performed to evaluate matrix deposition. Results At 24 h after LD or BP treatment, 1× and 0.75× physiological doses of LD and BP showed significant cytotoxicity in all the tested adult stem/progenitor cells. At 0.5×, BP resulted in higher viability than the same dose LD, with variance between cell types. Overall, the gene expressions associated with fibrogenic, chondrogenic, osteogenic, and adipogenic differentiation were attenuated in LD or BP pre-treated stem/progenitor cells, with notable dose-effect and dependence on types. In contrast, certain doses of LD and/or BP were found to increase specific gene expression, depending on the cell types. Conclusion Our data suggest that LAs such as LD and BP affect not only the viability but also the differentiation capacity of adult stem/progenitor cells from various anatomical sites. This study sheds light on stem cell applications for tissue regeneration in which isolation and transplantation of stem cells frequently involve LA administration.

show abstract

“…Interactions have been observed in other drugs commonly used in clinical practice. Li et al documented that ropivacaine inhibits cellular viability and induces apoptosis, whereas concomitant use of sufentanil mitigates its action by means of miRNA-182-5p/BCL10/CYCS regulation (160). Qu et al suggest that the beneficial effects of lidocaine on colorectal cancer could be mediated by the upregulation of miRNA-520 a-3p and targeting EGFR (161).…”

Section: Mirnas and Drugs Used During Anesthetic Proceduresmentioning

confidence: 99%